Mobile app to help patients with atrial fibrillation take their medication
The ReInforcement of Adherence Via Self-monitoring App Orchestrating Biosignals and Medication of RivoXaban in Patients with Atrial Fibrillation and Co-morbidities: Randomised Control Study(RIVOX-AF Study)
This study tests whether a mobile app can help people with atrial fibrillation remember to take their medication on time better than standard treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 1042 (estimated) |
| Ages | 19 Years and up |
| Sex | All |
| Sponsor | Seoul National University Bundang Hospital Academic / other |
| Locations | 1 site (Seongnam) |
| Trial ID | NCT05557123 on ClinicalTrials.gov |
What this trial studies
The RIVOX-AF study is a multicenter, randomized controlled trial designed to improve medication adherence among patients with atrial fibrillation (AF) using a mobile app. Participants will be divided into two groups: one receiving feedback and reminders through the app and the other receiving conventional treatment. The app aims to enhance patient engagement and ensure timely medication intake. Eligible patients include those aged 19 and older with AF and certain comorbidities who are able to use a smartphone.
Who should consider this trial
Good fit: Ideal candidates are patients aged 19 and older with atrial fibrillation and one or more comorbidities who can use a smartphone.
Not a fit: Patients with severe renal impairment, significant mitral valve issues, or those with legal or psychiatric problems may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve medication adherence and health outcomes for patients with atrial fibrillation.
How similar studies have performed: Other studies have shown promise in using mobile apps to improve medication adherence, suggesting this approach could be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with AF aged 19 years or older with one or more comorbidities including heart failure, myocardial infarction, stable angina, hypertension or diabetes mellitus (Patients can be enrolled 3 months after myocardial infarction or percutaneous coronary intervention). * patients who already took or plan to take rivoxban * patients who able to use smart phone Exclusion Criteria: * creatinine clearance \<15ml/min * moderate or severe mitral stenosis * mitral valve operation history * current alcohol abuse or alcohol abus history * Not eligible for study due to legal or psychiatric problem * enrolled other clinical study within 4 weeks * declined to enroll the study
Where this trial is running
Seongnam
- Seoul National University Bundang Hospital — Seongnam, South Korea (Recruiting)
Study contacts
- Study coordinator: Dong-Ju Choi, MD, PhD
- Email: djchoi@snubh.org
- Phone: +82317877007
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.